AACR establishes Cancer Evolution Working Group

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research has established the Cancer Evolution Working Group. 

The mission of the AACR Cancer Evolution Working Group is to advance cancer diagnostic, therapeutic, and prevention strategies by fostering a fundamental understanding of cancer evolution amongst its members and the broader cancer research community. Membership in the AACR Cancer Evolution Working Group is free and open to all members of the AACR interested in cancer evolution.

The AACR Cancer Evolution Working Group will strive to accomplish its mission by working to:

  • Facilitate transdisciplinary approaches to the study of cancer evolution and translate novel cancer evolution insights into new early detection, diagnostic, therapeutic, and preventive strategies to improve outcomes significantly and sustainably for cancer patients.
  • Promote the incorporation of multiomic molecular (genetic, epigenetic, genomic, karyotype, transcriptomic, proteomic, epiproteomic, metabolic), cellular, and tissue-based concepts and techniques, as well as novel data science tools into well-designed cancer evolution studies of multiclonal cancer cells and of host immune system and tumor microenvironment co-development.
  • Recommend scientific and educational programs to provide ongoing forum(s) for the scholarly discussion and development of effective approaches to the conduct and interpretation of cancer evolution studies, including an annual Cancer Evolution Special Conference, an ongoing monthly Cancer Evolution Seminar Series, and cancer evolution sessions at AACR Annual Meetings.
  • Foster collaborations with individuals interested in this scientific area and with relevant AACR scientific working groups that are engaged in other scientific disciplines.
  • Assist with the professional advancement of early- and mid-career investigators engaged in cancer evolution research.
  • Establish a community of cancer evolution experts and other individuals interested in advancing progress in cancer evolution.

AACR Cancer Evolution Working Group Executive Committee members are: 

  • Frank H. Laukien, PhD (co-chair)
  • Charles Swanton, MBPhD, FRCP, FMedSci, FRS, FAACR (co-chair)
  • Anna D. Barker, PhD, FAACR (co-chair elect)
  • Jeffrey P. Townsend, PhD (co-chair lect)
  • Denis Noble, CBE, FRS, FMedSci, MAE
  • Kenneth J. Pienta, MD
  • George H. Poste, DVM, PhD, FRCPath, FMedSci, CBE, FRS
  • Susan M. Rosenberg, PhD
  • Jason A. Somarelli, PhD
  • AACR Cancer Evolution Working Group Steering Committee members are: 
  • M. William Audeh, MD, MS
  • Alberto Bardelli, PhD
  • Michael C. Campbell, PhD
  • Peter J. Campbell, MBChB, PhD
  • Christina Curtis, PhD
  • James V. DeGregori, PhD
  • Robert A. Gatenby, MD
  • Marco Gerlinger, MD
  • Michael A. Gillette, MD, PhD
  • Robert J. Gillies, PhD
  • Trevor Graham, PhD
  • Henry H. Q. Heng, PhD
  • Giulia C. Kennedy, PhD
  • Carlo C. Maley, PhD
  • Perry S. Marshall, BS
  • Andriy Marusyk, PhD
  • Nicholas McGranahan, PhD
  • Franziska Michor, PhD
  • Paul S. Mischel, MD
  • Nicholas E. Navin, PhD
  • Serena Nik-Zainal, MBBCh, PhD
  • Larry Norton, MD, FAACR
  • Elizabeth O’Day, MPhil, PhD
  • Azra Raza, MD
  • Chan Soon-Shiong Professor of Medicine; Director, Myelodysplastic Syndrome Center, Columbia University, New York, NY
  • Andrea Sottoriva, PhD
  • Danny R. Welch, PhD
  • Jonathan Weissman, PhD
Table of Contents

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login